News

Current

Information

Acquistion of Arevipharma by Yonsung Group

The Active Pharmaceutical Ingredient (API) business of Arevipharma at their Radebeul site will be extended by innovation and investments, with strategic focus on outstanding quality, customer service as well as secured supplies and supply chains Radebeul, Germany – by 1st of January 2021 the acquisition of Arevipharma by Yonsung Group…

Certificate of suitability received R0-CEP 2018-070-Rev 00

In April 2019, Arevipharma have received its Certificate of Suitability for Remifentanil Hydrochloride thus being one of the first global suppliers of this API with a CEP. A fact Arevipharma are justifiably proud of. Arevipharma are one of the largest German manufacturers of narcotic generics. The production of narcotics at…
Successful FDA Inspection

Successful FDA Inspection

Dear Stakeholders, This is to inform you that our site in Radebeul, Germany, was inspected by the US Food and Drug Administration (US-FDA) from 25. – 29. April 2016. The audit has covered quality systems, equipment and facilities, materials, production, packaging, labeling and laboratory controls. We are proud to announce…

We are happy to advise you

We are looking forward to your inquiry
regarding our active ingredient portfolio or your CDMO project.